## **Georg Breier**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6925694/publications.pdf Version: 2024-02-01



CEODC RDELED

#	Article	IF	CITATIONS
1	The Influence of VE-Cadherin on Adhesion and Incorporation of Breast Cancer Cells into Vascular Endothelium. International Journal of Molecular Sciences, 2021, 22, 6049.	4.1	8
2	Microenvironmentally-driven Plasticity of CD44 isoform expression determines Engraftment and Stem-like Phenotype in CRC cell lines. Theranostics, 2020, 10, 7599-7621.	10.0	11
3	Cellular Automaton Modeling of Tumor Invasion. , 2020, , 851-863.		2
4	Hematopoietic hypoxiaâ€inducible factor 2α deficiency ameliorates pathological retinal neovascularization <i>via</i> modulation of endothelial cell apoptosis. FASEB Journal, 2019, 33, 1758-1770.	0.5	15
5	Cellular Automaton Modeling of Tumor Invasion. , 2019, , 1-13.		ο
6	The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor–endothelial cell interactions. Histochemistry and Cell Biology, 2018, 149, 15-30.	1.7	24
7	PHD3 Acts as Tumor Suppressor in Mouse Osteosarcoma and Influences Tumor Vascularization via PDGF-C Signaling. Cancers, 2018, 10, 496.	3.7	5
8	Heparanase and Thrombin: Common Signalling Pathways in Melanoma Cells?. Thrombosis and Haemostasis, 2018, 118, 1688-1689.	3.4	0
9	Haematopoietic prolyl hydroxylaseâ€1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. Journal of Pathology, 2017, 241, 547-558.	4.5	32
10	Angiogenesis in metabolic-vascular disease. Thrombosis and Haemostasis, 2017, 117, 1289-1295.	3.4	17
11	Receptor tyrosine kinase inhibitors: Are they real tumor killers?. International Journal of Cancer, 2016, 138, 540-554.	5.1	26
12	Adipocyte-Specific Hypoxia-Inducible Factor 2α Deficiency Exacerbates Obesity-Induced Brown Adipose Tissue Dysfunction and Metabolic Dysregulation. Molecular and Cellular Biology, 2016, 36, 376-393.	2.3	63
13	VEGFR2 Signaling Prevents Colorectal Cancer Cell Senescence to Promote Tumorigenesis in Mice With Colitis. Gastroenterology, 2015, 149, 177-189.e10.	1.3	44
14	Endothelial cadherins in cancer. Cell and Tissue Research, 2014, 355, 523-527.	2.9	62
15	The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®). International Journal of Oncology, 2014, 45, 2267-2277.	3.3	10
16	PHD4 Stimulates Tumor Angiogenesis in Osteosarcoma Cells via TGF-α. Molecular Cancer Research, 2013, 11, 1337-1348.	3.4	20
17	HIF-1α is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2α–induced excessive erythropoiesis. Blood, 2013, 121, 1436-1445.	1.4	67
18	HIF prolyl hydroxylase 2 (PHD2) is a critical regulator of hematopoietic stem cell maintenance during steady-state and stress. Blood, 2013, 121, 5158-5166.	1.4	41

#	Article	IF	CITATIONS
19	Lack of vascular endothelial growth factor receptor-2/Flk1 signaling does not affect substantia nigra development. Neuroscience Letters, 2013, 553, 142-147.	2.1	3
20	Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nature Cell Biology, 2013, 15, 249-260.	10.3	221
21	A role for prolyl hydroxylase domain proteins in hippocampal synaptic plasticity. Hippocampus, 2013, 23, 861-872.	1.9	19
22	Loss of Epithelial Hypoxia-Inducible Factor Prolyl Hydroxylase 2 Accelerates Skin Wound Healing in Mice. Molecular and Cellular Biology, 2013, 33, 3426-3438.	2.3	61
23	Mechanoinduction of lymph vessel expansion. EMBO Journal, 2012, 31, 788-804.	7.8	134
24	HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGFβ activation. Cancer Biology and Therapy, 2012, 13, 216-223.	3.4	21
25	Neuron-Specific Prolyl-4-Hydroxylase Domain 2 Knockout Reduces Brain Injury After Transient Cerebral Ischemia. Stroke, 2012, 43, 2748-2756.	2.0	65
26	Identification of a clonally expanding haematopoietic compartment in bone marrow. EMBO Journal, 2012, 32, 219-230.	7.8	70
27	Multimarker Gene Analysis of Circulating Tumor Cells in Pancreatic Cancer Patients: A Feasibility Study. Oncology, 2012, 82, 3-10.	1.9	104
28	Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression. Breast Cancer Research, 2012, 14, R154.	5.0	33
29	Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. Journal of Translational Medicine, 2012, 10, 222.	4.4	52
30	Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia. Thrombosis and Haemostasis, 2012, 108, 1-2.	3.4	10
31	Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine. Breast Care, 2012, 7, 7-12.	1.4	41
32	Overexpression of factor inhibiting HIFâ€1 enhances vessel maturation and tumor growth <i>via</i> plateletâ€derived growth factorâ€C. International Journal of Cancer, 2012, 131, E603-13.	5.1	30
33	Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clinical Laboratory, 2012, 58, 373-84.	0.5	12
34	Parameter estimation with a novel gradient-based optimization method for biological lattice-gas cellular automaton models. Journal of Mathematical Biology, 2011, 63, 173-200.	1.9	15
35	Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth in Mice through the Antiproliferative Activity of TGFÎ <sup>2</sup> . Cancer Research, 2011, 71, 3306-3316.	0.9	66
36	Cardiomyocyte-specific Prolyl-4-hydroxylase Domain 2 Knock Out Protects from Acute Myocardial Ischemic Injury. Journal of Biological Chemistry, 2011, 286, 11185-11194.	3.4	74

#	Article	IF	CITATIONS
37	Ablation of cholesterol biosynthesis in neural stem cells increases their VEGF expression and angiogenesis but causes neuron apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8350-8355.	7.1	64
38	BIOLOGISTICS AND THE STRUGGLE FOR EFFICIENCY: CONCEPTS AND PERSPECTIVES. International Journal of Modeling, Simulation, and Scientific Computing, 2009, 12, 533-548.	1.4	33
39	A novel Flk1-TVA transgenic mouse model for gene delivery to angiogenic vasculature. Transgenic Research, 2008, 17, 403-415.	2.4	6
40	Vascular Endothelial Cadherin Promotes Breast Cancer Progression via Transforming Growth Factor β Signaling. Cancer Research, 2008, 68, 1388-1397.	0.9	96
41	Tracking Adult Neovascularization during Ischemia and Inflammation Using Vegfr2-LacZ Reporter Mice. Journal of Vascular Research, 2008, 45, 437-444.	1.4	10
42	Spatiotemporal Expression of flk-1 in Pulmonary Epithelial Cells during Lung Development. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 163-170.	2.9	14
43	Judah Folkman. Thrombosis and Haemostasis, 2008, 99, 250.	3.4	1
44	HIF in Vascular Development and Tumour Angiogenesis. Novartis Foundation Symposium, 2007, 283, 126-138.	1.1	6
45	Lentiviral Rescue of Vascular Endothelial Growth Factor Receptor-2 Expression in <i>Flk1</i> â^'/â^' Embryonic Stem Cells Shows Early Priming of Endothelial Precursors. Stem Cells, 2007, 25, 2987-2995.	3.2	14
46	Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. International Journal of Cancer, 2007, 120, 1899-1908.	5.1	44
47	Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Experimental Cell Research, 2007, 313, 1-9.	2.6	194
48	Continuous Endothelial Cell Activation Increases Angiogenesis: Evidence for the Direct Role of Endothelium Linking Angiogenesis and Inflammation. Journal of Vascular Research, 2006, 43, 193-204.	1.4	65
49	Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development. Blood, 2006, 107, 584-590.	1.4	68
50	Lymphangiogenesis in vitro. Blood, 2006, 107, 853-854.	1.4	0
51	Isolated Pancreatic Islets in Three-Dimensional Matrices are Responsive to Stimulators and Inhibitors of Angiogenesis. Cell Transplantation, 2006, 15, 489-497.	2.5	16
52	Notch, hypoxia and arterial cell fate. Vascular Pharmacology, 2006, 45, 177-178.	2.1	0
53	Type I Collagen Limits VEGFR-2 Signaling by a SHP2 Protein-Tyrosine Phosphatase–Dependent Mechanism 1. Circulation Research, 2006, 98, 45-54.	4.5	55
54	Vascular Endothelial Growth Factor Increases Functional β-Cell Mass by Improvement of Angiogenesis of Isolated Human and Murine Pancreatic Islets. Transplantation, 2005, 79, 1530-1536.	1.0	135

#	Article	IF	CITATIONS
55	Lymphangiogenesis in Regenerating Tissue. Circulation Research, 2005, 96, 1132-1134.	4.5	14
56	Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thrombosis and Haemostasis, 2004, 91, 595-605.	3.4	179
57	Angiopoietin-2 Causes Pericyte Dropout in the Normal Retina. Diabetes, 2004, 53, 1104-1110.	0.6	306
58	Endotheliumâ€specific Cre recombinase activity in flkâ€1â€Cre transgenic mice. Developmental Dynamics, 2004, 229, 312-318.	1.8	47
59	Inhibition of solid tumor growth by gene transfer of VEGF receptorâ€1 mutants. International Journal of Cancer, 2004, 111, 348-357.	5.1	48
60	In Situ Hybridization Analysis of Vascular Endothelium. , 2004, , 301-312.		0
61	Circulating Vascular Progenitor Cells Do Not Contribute to Compensatory Lung Growth. Circulation Research, 2003, 93, 372-379.	4.5	79
62	p38 MAP Kinase—a molecular switch between VEGFâ€induced angiogenesis and vascular hyperpermeability. FASEB Journal, 2003, 17, 262-264.	0.5	159
63	Cooperative Interaction of Hypoxia-inducible Factor-2α (HIF-2α) and Ets-1 in the Transcriptional Activation of Vascular Endothelial Growth Factor Receptor-2 (Flk-1). Journal of Biological Chemistry, 2003, 278, 7520-7530.	3.4	239
64	Hemogenic and nonhemogenic endothelium can be distinguished by the activity of fetal liver kinase (Flk)–1promoter/enhancer during mouse embryogenesis. Blood, 2003, 101, 886-893.	1.4	68
65	Transforming growth factorâ€Î² and Ras regulate the VEGF/VEGFâ€receptor system during tumor angiogenesis. International Journal of Cancer, 2002, 97, 142-148.	5.1	99
66	Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1. Laboratory Investigation, 2002, 82, 473-481.	3.7	18
67	The Role of Vascular Endothelial Growth Factors and Their Receptors During Embryonic Vascular Development. , 2002, , 21-54.		4
68	Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. Journal of Clinical Investigation, 2002, 109, 777-785.	8.2	171
69	Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. Journal of Clinical Investigation, 2002, 109, 777-785.	8.2	106
70	Angiogenesis in Embryonic Development—A Review. Placenta, 2000, 21, S11-S15.	1.5	131
71	Role of SCL/Tal-1, GATA, and Ets transcription factor binding sites for the regulation of Flk-1 expression during murine vascular development. Blood, 2000, 96, 3078-3085.	1.4	136
72	Functions of the VEGF/VEGF Receptor System in the Vascular System. Seminars in Thrombosis and Hemostasis, 2000, 26, 553-560.	2.7	46

#	Article	IF	CITATIONS
73	De novo expression of vascular endothelial growth factor and its receptors in human pancreatic cancer: Evidence for a novel autocrine mitogenic loop. Gastroenterology, 2000, 118, A447.	1.3	Ο
74	De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology, 2000, 119, 1358-1372.	1.3	169
75	Endothelial Receptor Tyrosine Kinases involved in Blood Vessel Development and Tumor Angiogenesis. Advances in Experimental Medicine and Biology, 2000, 476, 57-66.	1.6	14
76	Role of SCL/Tal-1, GATA, and Ets transcription factor binding sites for the regulation of Flk-1 expression during murine vascular development. Blood, 2000, 96, 3078-3085.	1.4	3
77	Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promoter/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice. Blood, 1999, 93, 4284-4292.	1.4	204
78	In situ Hybridization with RNA Probes. , 1999, 96, 107-117.		8
79	Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathology and Applied Neurobiology, 1999, 25, 104-112.	3.2	100
80	Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promoter/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice. Blood, 1999, 93, 4284-4292.	1.4	139
81	Upregulation of vascular endothelial growth factor in severe chronic brain hypoxia of the rat. Neuroscience Letters, 1998, 252, 199-202.	2.1	28
82	Thrombopoietin stimulates VEGF release from câ€Mplâ€expressing cell lines and haematopoietic progenitors. FEBS Letters, 1998, 423, 10-14.	2.8	29
83	Vascular Endothelial Growth Factor Induces Endothelial Fenestrations In Vitro. Journal of Cell Biology, 1998, 140, 947-959.	5.2	580
84	Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat Diabetes, 1998, 47, 401-406.	0.6	211
85	The Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis. , 1998, , 305-318.		0
86	VEGF Gene Transfer Reduces Intimal Thickening via Increased Production of Nitric Oxide in Carotid Arteries. Human Gene Therapy, 1997, 8, 1737-1744.	2.7	196
87	2.W12.5 Adventitial gene transfer to rabbit carotid arteries. Atherosclerosis, 1997, 134, 109-110.	0.8	0
88	Insights in Vessel Development and Vascular Disorders Using Targeted Inactivation and Transfer of Vascular Endothelial Growth Factor, the Tissue Factor Receptor, and the Plasminogen System. Annals of the New York Academy of Sciences, 1997, 811, 191-206.	3.8	119
89	Genetic mapping of the vascular endothelial growth factor (Vegf) gene to mouse Chromosome 17. Mammalian Genome, 1997, 8, 451-452.	2.2	3
90	Angiogenesis in Embryos and Ischemic Diseases. Thrombosis and Haemostasis, 1997, 78, 678-683.	3.4	115

#	Article	IF	CITATIONS
91	Polyoma Middle T-induced Vascular Tumor Formation: The Role of the Plasminogen Activator/Plasmin System. Journal of Cell Biology, 1997, 137, 953-963.	5.2	65
92	The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities. Journal of Biological Chemistry, 1996, 271, 17629-17634.	3.4	749
93	The role of vascular endothelial growth factor in blood vessel formation. Trends in Cell Biology, 1996, 6, 454-456.	7.9	141
94	Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996, 380, 435-439.	27.8	3,776
95	Role of tissue factor in embryonic blood vessel development. Nature, 1996, 383, 73-75.	27.8	646
96	Characterization of the Endothelium-Specific Murine Vascular Endothelial Growth Factor Receptor-2 (Flk-1) Promoter. Circulation Research, 1996, 79, 277-285.	4.5	64
97	Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes Journal of Biological Chemistry, 1995, 270, 12607-12613.	3.4	627
98	Hypoxia-induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells. Journal of Biological Chemistry, 1995, 270, 19761-19766.	3.4	488
99	Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor 2(flk-1) Are Expressed during Vasculogenesis and Vascular Differentiation in the Quail Embryo. Developmental Biology, 1995, 169, 699-712.	2.0	253
100	Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Letters, 1995, 358, 311-315.	2.8	150
101	Coordinate expression of vascular endothelial growth factor receptor-1 (fit-1) and its ligand suggests a paracrine regulation of murine vascular development. Developmental Dynamics, 1995, 204, 228-239.	1.8	269
102	Molecular Mechanisms of Developmental and Tumor Angiogenesis. Brain Pathology, 1994, 4, 207-218.	4.1	217
103	Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible <i>In vivo</i> regulatory mechanisms. International Journal of Cancer, 1994, 59, 520-529.	5.1	429
104	Angiogenic Growth Factors in Embryos and Tumors. Contributions To Oncology / Beitrage Zur Onkologie, 1992, 44, 224-231.	0.1	2
105	Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 1992, 359, 845-848.	27.8	2,168
106	The role of growth factors in angiogenesis. Journal of Molecular and Cellular Cardiology, 1991, 23, S17.	1.9	0